<SEC-DOCUMENT>0001193125-23-176373.txt : 20230628
<SEC-HEADER>0001193125-23-176373.hdr.sgml : 20230628
<ACCEPTANCE-DATETIME>20230627190855
ACCESSION NUMBER:		0001193125-23-176373
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230627
FILED AS OF DATE:		20230628
DATE AS OF CHANGE:		20230627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231048845

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d435302d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated 6/27/2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d435302dex991.htm">Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibito </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: 6/27/2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d435302dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g435302g81t07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Secures Third United States Patent for Eftilagimod Alpha </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in Combination with a <FONT STYLE="white-space:nowrap">PD-1</FONT> Pathway Inhibitor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 27</B><B></B><B>&nbsp;June </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) entitled &#147;Combined Preparations for the Treatment of Cancer
or Infection&#148; by the United States Patent Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This United States patent was filed as a second divisional application and follows the grant of
the United States parent patent and first divisional patent announced in December 2020 and March 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The claims of the new patent build
on the protection provided by the two previously granted patents, and are directed to methods of treating cancer by administering Immutep&#145;s lead active immunotherapy candidate eftilagimod alpha (&#147;efti&#148;) and a <FONT
STYLE="white-space:nowrap">PD-1</FONT> pathway inhibitor, specifically <FONT STYLE="white-space:nowrap">BMS-936559,</FONT> durvalumab, atezolizumab or avelumab. The expiry date of the patent is 15&nbsp;November 2036 (including 312 days of patent
term adjustment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We continue to build our patent estate around lead candidate efti, which is a unique biomolecule and shows great promise in being
able to ultimately help diverse sets of cancer patients, including those with more complex needs. Here we add another key US patent which is closely aligned with our clinical development pipeline. These key patents support ongoing investment and
allow us to confidently push forward across all of our business functions, including clinical, manufacturing, and business development,&#148; said Marc Voigt, CEO of Immutep. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A continuation application and a further divisional application have been filed to pursue other embodiments of the invention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator that
stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to and activates antigen-presenting cells via MHC II molecules leading to expansion and proliferation of CD8<SUP STYLE="font-size:75%; vertical-align:top">+
</SUP>(cytotoxic) T cells, CD4<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> (helper) T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like
<FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration
(FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g435302g81t07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more
information, please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the CEO of Immutep Limited. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George
Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g435302g81t07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g435302g81t07.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4=>K\CZM1LX]S_0D5[.RC_>/L-(\G+M/5?=<DH&% !0 4 % !0 4 % !0 4
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M_AT_*$?R-2M#8* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H ^?OV@?@Q=_&/P_H^G:?KD.C7VB:E+?0?:X))[&Z2>W^S2
MQS"%@\4J+@HX5QC>C+B3*GZ!^AW'PE\ ?\*Q\":'X-;43JLNEI=M/>^4T$<L
MU[?7%]*L$+2.8K>-[@HH9V9MI=L,Y -OD&WR/2"0O7C_ .M0  @].WX4 !(7
MKQ_]:@ !!Z=OPH 6@!"0O7C_ .M0  @].WX4 !(7V_\ K4  (/3M^% "T %
M!0 AZ'MP?PH _.7Q'\?OB@GQ[B\!6NNP6'ANW^).F^'C:6NE:<9KC2VURVLY
M8+B\N+>28F2!F5GB>(\DCGF@#]&5Z>F#CZ8X_I0 Z@!"0H)/ 49.>, =:  $
M$<$$=L<T +0 F<'%  >G^>U ;?(^?/C5\(3X\2UUO1OL\7B/2XO)\BX?R+;5
MK)7\Q;.>88\F=&>3RI3@8E=6(Q&T7GX[!/$\LX1YIPZ+=^5SYK/\B69*%:C&
M^(I6<8K3FMK9_+N?+'C#P)X_U35]UK\-=8T.T@MK:SM]+TRVEU&P@\A2)&CN
M;2,PMYDS-(2#U8G).2?#K8;&.24,-.*I^MOGTL?'YC@<WK8E.G@:L:48*FX0
MNHMKRC9'IGPE^ NNOJNGZ]XYMC8:=IDRW-CHD\JRW=S<1OY\3742,Z6=HLX6
M0QL1)(RX9 C$MZ&#RZI>%6JN5QZ/T:V/3R/AK&NK2Q6:OV-.@VZ="6K:<7%:
M/:U[_(^VT& !P-O''&,#BO<4>1*/8_04HKE4-HZ?A8DH&% !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M1;J(H-1M+A9/LFKV\'/D^9)#+'-$IVI(@90B2HBGZ!^A])T % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?(G
M[5O_ ""?"'_82U7_ -)[>O'SG^!0_P ?^1\1QK_"PO\ B?Y(ZSX/_P#)"O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!+]6KLP/\ R+5Z,][)/^2=P?\ A?YL^:_V9?\ DH\O_8MZG_Z4Z;7DY/\
M[Y+_  L^0X,_Y&M7_KW+]#Z#_::_Y)L/^Q@TO_T3>5ZV9_[M\U^I]1Q;_P B
MBI_C7ZF+^RS_ ,B5KO\ V-$__IHT>L,I_P!VJ_XSDX,_W'$?XC@OVK?^0UX/
M_P"P?J?_ *5VE<^=?Q:'^%GG\;?Q,+_A/H/X:Z;!J_P@\.:7=#-MJ/A3^SYP
M!DF"]M9;:8#GKY<C5Z^"TPV&\H'UF2?\BO!^4#\NO"^L^*/V;_BU)-J>DO<7
M6C27VFZA82L;:'6M%NOD6YL;ORF'ERB*"Z@F"NN^-0R\.AZ=CUMCVCXV?M1^
M%_B?\/;[PAI?AO7M-O;^YTNX-UJ$NG&TA^P7L%W(@-M<.\I;RBBG8G)R<8Q0
M!Z9^PQQX6\>8[:_IF.W33)L4 ?.G[1>B:U\/_CI>^)XK9HX-1U?3_&/AZ[DC
M;[+/<6[VES=1%\!?,@U:"</%G<$>)R LJF@#Z+'[<OA:/2D8>!O$#ZQY*^9:
MF_T^+31<!,,JZAF2?R<J<,UF&QMR.I ![+\;O __  NKX1P_V#L?4C;Z9XN\
M-*[(BW4S6+R+9M*Y"H;G3;VYB4LP42O$S$*IH_0/T/@[X+?'G7_@5=:MX7U[
MP[>7^BRZBUQ?:+.S:=J^BZJJ);W,MN+B(@%XXHA+;3*@8PHZNC;O,-@V/H[4
MOVY_"L=JW]C^!O$%U>;?ECU._P!-TZU#X_BGM6O7V@X_Y9*QYP!0!]#?$[5(
MM;^!'C/68 !!JWPZU+4H #D"*^T,W4>#@9&R48/IB@#\PO@+\8XO@UXCU+5K
MG0Y-;LM7TV/3KN*"[6SNK98KF.Y6XMVEB>.9MRA6C?9D,"'4@Y-@V/;OC#^U
MW!XU\):EX3\(>'M1T9=<MGL=6U35Y[7SUTV5=MW9V-M9R2*6N(BT+SR2C;&[
MA8]S!U /2/V-/A=J?AZQU;X@Z[9S6,VOVL6F>'K>X0Q7!T=9DNKO47C==RQ7
M=Q':+%D*66T,F-DB,QMY!MY'W90 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MX([Z29(7! (**I7 QBC;R#;R/6%4( J@ +P .  !@  =@!0 M !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MLM"^)=ZNLZS<7&CS^([/3'OM0GNQ9PV&C6UY;&))RR^>D\DC>:RLQW $D**
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M1!&LD[@ F^,$!M?@O\0[8RS3F#P)KL)GN&#SSF/29E,LS@#?,Q!+-@98D]Z
M/B;]AG_D<_&O_8KV7_IUAH _3*@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "9'J*/T"WX"T % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M %ESC_GZ'_"_OBM_T,R_^"?0_P#Y74?VGC?Y@_UESC_GZ'_"_OBM_P!#,O\
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M/^?H?\+^^*W_ $,R_P#@GT/_ .5U']IXW^8/]9<X_P"?H?\ "_OBM_T,R_\
M@GT/_P"5U']IXW^8/]9<X_Y^A_PO[XK?]#,O_@GT/_Y74?VGC?Y@_P!9<X_Y
M^A_PO[XK?]#,O_@GT/\ ^5U']IXW^8/]9<X_Y^A_PO[XK?\ 0S+_ ."?0_\
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M_OBM_P!#,O\ X)]#_P#E=1_:>-_F#_67./\ GZ'_  O[XK?]#,O_ ()]#_\
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M1_:>-_F#_67./^?H?\+^^*W_ $,R_P#@GT/_ .5U']IXW^8/]9<X_P"?H?\
M"_OBM_T,R_\ @GT/_P"5U']IXW^8/]9<X_Y^A_PO[XK?]#,O_@GT/_Y74?VG
MC?Y@_P!9<X_Y^A_PO[XK?]#,O_@GT/\ ^5U']IXW^8/]9<X_Y^A_PO[XK?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!+#_ *Z+_KHG_H0JZ?QQ
1_KH:T/XU+_$C[BKU#ZP__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
